Quantum BioPharma Ltd. (NASDAQ: QNTM) has received U.S. Food and Drug Administration approval of its Investigational New Drug application for Lucid-MS, allowing the company to proceed with Phase 2 clinical testing of its multiple sclerosis candidate. The planned randomized, double-blind, placebo-controlled study will evaluate the drug's efficacy, safety and tolerability in patients with MS, with researchers assessing clinical symptoms and changes visible through brain imaging. The clearance matters because it moves a potentially differentiated MS therapy into mid-stage human testing, a critical hurdle for any experimental neurological treatment.
Unlike many existing MS therapies that target the immune system, Lucid-MS is designed to protect nerve cells by inhibiting PAD2, an enzyme associated with myelin damage. That mechanism could offer a different therapeutic approach for a disease where current treatments largely modulate immune activity rather than directly defend myelin. The compound previously completed Phase 1 trials in healthy volunteers, where the company reported a favorable safety profile and good tolerability, providing a foundation for the upcoming patient study. For investors, the FDA's decision reduces regulatory uncertainty around the program and validates the company's preclinical work on myelin protection.
Quantum BioPharma describes itself as a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The company also invented UNBUZZD and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.48% ownership stake as of June 30, 2026, at www.unbuzzd.com, along with royalty payments of 7% of sales until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM. The announcement was distributed through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences and life sciences. BioMedWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire, editorial syndication to more than 5,000 outlets, press release enhancement, social media distribution and tailored corporate communications solutions. For full terms and disclaimers applicable to BioMedWire content, see https://www.BioMedWire.com/Disclaimer.
